{"adverse_reactions":["ADVERSE REACTIONS On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued. Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted. Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride have been used to inhibit pre-term labor. Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received Isoxsuprine Hydrochloride. Pulmonary edema has been reported in mothers treated with beta stimulants. Isoxsuprine Hydrochloride is neither approved nor recommended for use in the treatment of premature labor."],"contraindications":["CONTRAINDICATIONS There are no known contraindications to oral use when administered in recommended doses. Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding."],"description":["DESCRIPTION Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with the following chemical structure: C 18 H 23 NO 3 ∙ HCl p-Hydroxy-α[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol hydrochloride. Quantitative Ingredient Information: Each tablet taken orally contains 10 or 20 mg Isoxsuprine HCl Pharmacological Class: Peripheral Vasodilator Chemical Structure"],"description_table":["<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><renderMultiMedia referencedObject=\"MM1\"/></td></tr><tr><td>C <sub>18</sub>H <sub>23</sub>NO <sub>3</sub> &#x2219; HCl  p-Hydroxy-&#x3B1;[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol hydrochloride. </td></tr></tbody></table>"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Oral: 10 to 20 mg, three or four times daily."],"effective_time":"20220829","how_supplied":["HOW SUPPLIED Isoxsuprine HCl Tablets, USP 10 mg are white, round, biconvex tablets identified as \"I10\" debossed on one side and bisected on the other. Bottle of 100 NDC 51293-606-01 Bottle of 1000 NDC 51293-606-10 Isoxsuprine HCl Tablets, USP 20 mg are white, round, biconvex tablets identified as \"20\" debossed on one side and bisected on the other. Bottle of 100 NDC 51293-605-01 Bottle of 1000 NDC 51293-605-10"],"how_supplied_table":["<table width=\"40%\" styleCode=\"Noautorules\"><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"60%\" align=\"left\" valign=\"top\"/><tbody><tr><td>Bottle of 100</td><td>NDC 51293-606-01</td></tr><tr><td>Bottle of 1000</td><td>NDC 51293-606-10</td></tr></tbody></table>","<table width=\"40%\" styleCode=\"Noautorules\"><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"60%\" align=\"left\" valign=\"top\"/><tbody><tr><td>Bottle of 100</td><td>NDC 51293-605-01</td></tr><tr><td>Bottle of 1000</td><td>NDC 51293-605-10</td></tr></tbody></table>"],"id":"e764c643-d253-1cd6-e053-2995a90a3e54","indications_and_usage":["INDICATIONS Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows: Possibly Effective For the relief of symptoms associated with cerebrovascular insufficiency. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation."],"openfda":{},"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL- 10 mg Bottle Label ECI Pharmaceuticals NDC 51293-606-01 Isoxsuprine Hydrochloride Tablets, USP 10 mg Rx only 100 Tablets PRINCIPAL DISPLAY PANEL- 10 mg Bottle Label","PRINCIPAL DISPLAY PANEL- 20 mg Bottle Label ECI Pharmaceuticals NDC 51293-605-01 Isoxsuprine Hydrochloride Tablets, USP 20 mg Rx only 100 Tablets PRINCIPAL DISPLAY PANEL- 20 mg Bottle Label"],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"precautions":["PRECAUTIONS Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"set_id":"6baec489-724b-4184-9529-7b9ca3573025","spl_product_data_elements":["ISOXSUPRINE HYDROCHLORIDE isoxsuprine hydrochloride LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN ISOXSUPRINE HYDROCHLORIDE ISOXSUPRINE I10 ISOXSUPRINE HYDROCHLORIDE isoxsuprine hydrochloride LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN ISOXSUPRINE HYDROCHLORIDE ISOXSUPRINE 20"],"spl_unclassified_section":["Rx Only","COMPOSITION Isoxsuprine HCl Tablets, 10 mg and 20 mg. These tablets contain the following Inactive Ingredients: Corn Starch, Lactose Monohydrate, Magnesium Stearate (Vegetable), Microcrystalline Cellulose.","Manufactured By: ECI Pharmaceuticals, LLC Fort Lauderdale, FL 33309 Iss. 04/12"],"version":"6"}